Abstract: An environmentally responsive Paecilomyces lilacinus microbead and its preparation method and application are provided. The Paecilomyces lilacinus microbead includes a capsule core and a capsule wall; wherein, in the capsule core, Paecilomyces lilacinus spore powder, a vegetable oil, glucose, peptone, a cellulose nanofiber, sodium citrate, and a surfactant are combined to form an emulsifiable capsule core; and in the capsule wall, chitosan, gelatin, polyvinyl alcohol, glycerol, and water are combined to form a water-responsive shell. The environmentally responsive Paecilomyces lilacinus microbeads can stimulate the dissolution of polyvinyl alcohol in the shell according to the moisture content in the soil, so that the water in the soil flows into the microbeads. The cellulose nanofibers in the microbeads absorb water and expand, blocking the holes in the shell, resulting in the inability of spores to flow out.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: Embodiments of the disclosure concern methods and compositions related to manipulation of the microbiome in an individual having at least one social behavior deficit. In particular embodiments, an individual has at least one social behavior deficit and was born from a mother who during pregnancy was obese, overweight, or on a high-fat diet during pregnancy or carries mutations associated with neurodevelopmental disorders. In specific embodiments, the individual having at least one social behavior deficit is provided an effective amount of Lactobacillus reuteri for the improvement of at least one symptom of a social behavior deficit.

Abstract: Described are probiotic compositions for human oral consumption comprising Veillonella bacteria. In some aspects, the probiotic compositions further comprise a salt of nitrate (NO3?) and/or a salt of nitrite (NO2?). In other aspects, the probiotic compositions further comprise a salt of nitrite (NO2?) and a natural source of nitrate. In certain embodiments, the probiotic compositions additionally comprises a polyphenol. Also described herein are methods of enhancing generation of bioactive nitrogen oxides in a human subject, of treating or preventing a gastrointestinal disorder in a human subject, of enhancing athletic performance in a human subject, and of enhancing administration of nitrite or nitrate in a human subject, wherein the human subject is administered the probiotic compositions described herein.

Abstract: The present disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria are grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

Abstract: Provided herein are novel Lactobacillus fermentum strains, NRRL B-67059 or NRRL B-67060, compositions containing the NRRL B-67059 or NRRL B-67060 strains, and fermented dairy products and bioactive compounds prepared using the NRRL B-67059 or NRRL B-67060 strains. Also provided are methods of modulating the immune system of a subject.

Abstract: The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome.

Abstract: The present disclosure relates to the use of autologous fecal samples obtained from a subject for use in prevention and/or treatment of microbial dysbiosis in the gastrointestinal tract in said subject and to related pharmaceutical compositions for oral administration. The disclosed autologous fecal samples are useful for treatment of microbial dysbiosis in the gastrointestinal tract associated with medical treatment and/or various indications, including chronic disease and infectious disease, for example Clostridium difficile infection.

Abstract: A media supplement for culturing anaerobic bacteria is provided which comprises a filtrate of eilluent from a chemostat vessel in which a target bacterial ecosystem has been culnn-ed. Methods of using the supplement for culturing or isolating anaerobic microbial strains or cormmmities, particularly anaerobic bacteria from the human gut, are also provided.

Abstract: Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

Abstract: Described herein are methods and compositions for the treatment of skin conditions associated the dysbiosis. Further described herein is the use of metabolites for treatment of dysregulated microbiota in a subject. Such metabolites can be produced by microorganisms present in a higher abundance in the skin of healthy subjects as compared to the skin of a subject having dysbiosis of the skin. In addition, compositions and methods provided herein describe the use of metabolites as part of a combination therapy.

Abstract: Bifidobacterium longum AH1362 (NCIMB 41715) produces a polysaccharide and increases energy excretion. The strain is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.

Abstract: The invention relates to compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. In certain aspects, the invention relates to immunogenic compositions (e.g., vaccines) to diminish the number or pathogenic effects of one or more bacteria associated with the development or progression of an inflammatory disease or disorder.

Abstract: The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus, in particular the strains B. lactis CECT 8145, B. longum ES1 CECT 7347 and/or L. rhamnosus CECT 8361, in the treatment and/or prevention of psoriasis outbreaks or psoriasis.

Abstract: A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a composition comprising pseudovitamin B12-producing bacteria, optionally in conjunction with mucin-degrading and/or propionate-producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vitamin B12 deficiency due to metformin treatment for type-2 diabetes, and to subjects having undergone bariatric surgery.

Abstract: Endophytic microbial strains as biocatalysts isolated from fresh plant samples, compositions, and methods of use thereof to enhance the growth and/or yield of a plant in the presence of reduced synthetic phosphate fertilizers are provided. Endophytic microbial strains serve as biocatalysts to solubilize mineral-P and mineralize organic-P otherwise unavailable to plants for their nutritional phosphate needs. Thus defined, biocatalysts, will serve to replace synthetic phosphate fertilizers. Also provided are materials and methods for inoculating plants with these biocatalysts at carefully selected inoculum densities to reliably reduce the amount of synthetic phosphate fertilizer by 50% thus accomplishing obtaining optimal yields in technically and cost-effective manner.

Abstract: A natural product for improving health and reducing the risk of death due to dangerous diseases comprises a presence of figs and Acetobacter pasteurianus.

Abstract: A formulation for vaginal administration comprising an effective amount of a composition of dried Lactobacillus cells and boric acid, with a carrier. The composition can include one or more antioxidants. Optionally, the composition is in a unit dosage form. Also provided are methods for making and using the composition.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide for use in preventing and/or treating constipation and/or in improving stool consistency/frequency in an infant or a young child.

Abstract: Provided are Christensenella intestinihominis and an application thereof, specifically, use of Christensenella intestinihominis in treating and preventing obesity and related diseases thereof. Also provided are a composition for treating and preventing obesity and related diseases thereof, comprising compositions of drugs, drinks, food, or animal feed, and a method for reducing weight and/or blood lipid.

Abstract: A spore-forming Bacillus species, and more particularly, a Bacillus subtilis strain identified as MB40 is provided. Compositions comprising the MB40 strain, methods of making products comprising the same, and methods of using the same are also provided.

Abstract: A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

Abstract: The therapeutic use of bacteria, specifically but not only lactobacilli, which produce indole-3-aldehyde, or directly of indole-3-aldehyde itself, is proposed as a means of prevention and treatment of immune dysreactive disorders in which the hyper-inflammatory or autoimmune component represents the basic element.

Abstract: This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: Provided are a new Paenibacillus sp. strain, the deposit number of which is CGMCC No. 8333, and a method for culturing the exopolysaccharide; and an exopolysaccharide having a structural formula as shown in formula (I) being produced by the strain, as well as a production method thereof and its use in promoting the propagation of bifidobacterium. The exopolysaccharide shown by formula (I) has a moderate degree of polymerization (DP=15-30) and has the functions of promoting the propagation of bifidobacterium, as well as adjusting human intestinal microflora.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: Method for lyophilisation of a simple of fecal microbiota. The present invention relates to a method for lyophilisation of a sample of fecal microbiota from a donor subject, comprising the following steps: A) mixing of a sample of fecal microbiota from a donor subject with a diluent selected from polyols, disaccharides to pentasaccharides, maltodextrins and mixtures thereof, and B) freezing the mixture obtained in A) at a temperature of less than ?50° C., preferably of between ?70° C. and ?100° C., followed by the lyophilisation thereof.

Abstract: The presently disclosed subject matter provides compositions, methods, and kits comprising shape memory particles that can be used for delivering a drug and/or treating a disease or disorder in a patient. Specifically, shape changes in the presently disclosed shape memory particles can be used to control drug delivery spatially and/or temporally in a patient. Also provided are compositions, methods, and kits comprising nanoparticles and hypoxia-inducible factor (HIF) inhibitors with or without chemotherapeutic agents for inhibiting HIF activity in a patient and/or treating a hypoxia-associated disease or disorder.

Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.

Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.

Abstract: The invention relates to the fields of application of health, biotechnology and nutrition, the aim of the invention being to provide a gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease, the characteristics and components thereof reducing the concentration of uremic toxins, improving the renal function of the patient with an increase in urea, creatinine, uric acid, p-cresols or indoles in the blood. The gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease is easier to administrate orally as it does not require the consumption of liquids for the administration thereof, reducing liquid retention. Another advantage of the present invention is the fact that it refers to live and active bacteria. The present invention is also used a primary source of food with known prebiotic effects, an element which is not considered in other inventions; it is not in a pharmaceutical form.

Abstract: Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human ?-lactalbumin.

Abstract: Inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone disease, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. Compositions and methods of the invention can increase lifespans in a simple, non-invasive manner.

Abstract: Provided are bioactive compounds and metabolites derived from Chromobacterium species culture responsible for controlling pests, compositions containing these compounds, methods for obtaining these compounds and methods of using these compounds and compositions for controlling pests.

Abstract: The present invention relates to methods of scalably producing microorganisms by propagating them within plant tissues and introducing them into agricultural seeds to improve their shelf-life during long-term storage, to produce substances of interest, and to create libraries of microbes.

Abstract: The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing and/or treating URT infections in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s) ii) the infant or young child has at least one sibling iii) the infant or young child was born by C-section.

Abstract: Methods of reducing milk glycans, and thus enteric pathogens that use such glycans as carbon sources, in the gut of nursing mammals.

Abstract: Disclosed herein is a composition containing turmeric starch for use as a prebiotic plant fiber. Also disclosed is a method to increase the viable counts of Bacillus coagulans MTCC 5856 by co-culturing with turmeric starch and the production of short chain fatty acids (SCFA) by Bacillus coagulans MTCC 5856 using turmeric starch.

Abstract: The invention relates to the cloning, sequencing and characterization of the gene responsible for Quorum Quenching (QQ) activity against Quorum Sensing (QS) signals of the Tenacibaculum sp. strain 20J (CECT7426). Said gene encodes a peptide having at least lactonase activity with a percentage of identity less than 38% with the lactonases described up until now for other species, as well as the sequences of the homologous genes present in other species of the genus Tenacibaculum. Said peptide shows a broad spectrum of activity degrading optionally substituted N-acyl-homoserine lactones (AHLs) of 4-14 carbon atoms in the side chain thereof, is active at pH comprised between 3 and 9, proteinase K- and chymotrypsin-resistant and does not interact with ?-lactam antibiotics.

Abstract: Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

Abstract: The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome.

Abstract: Disclosed herein is (i) a method related to the growth promotional activity of plant based fibers on Bacillus coagulans MTCC 5856; (ii) the combination of plant based fibers and Bacillus coagulans MTCC 5856 to inhibit Gram Negative pathogenic bacteria; and (iii) the production of short chain fatty acids (SCFA) by Bacillus coagulans MTCC 5856 using plant based fibers.

Abstract: Selection of probiotic strains belonging to the genus Bifidobacterium and to a symbiotic composition containing the same for use of feeding infants, is described.

Abstract: A formulation for vaginal administration comprising an effective amount of a composition of dried Lactobacillus cells and boric acid, with a carrier. The composition can include one or more antioxidants. Optionally, the composition is in a unit dosage form. Also provided are methods for making and using the composition.

Abstract: A cannabinoid composition having an excipient including ?-tocopherol and at least one isolated cannabinoid having a purity of greater than 80%. The ?-tocopherol inhibits oxidation, regulates viscosity of the composition, and improves bioavailability of the cannabinoid. The composition includes a carrier oil mixed with the excipient and cannabinoid. In one embodiment, the at least one cannabinoid is an isolated cannabinoid having a greater than 80% purity, and preferably greater than 90% purity. The at least one cannabinoid is selected from the group consisting of phytocannabinoids, endocannabinoids, synthetic cannabinoids, and combinations thereof. The cannabinoid may be derived from plants other than cannabis sativa, or synthesized from fungi, bacteria, yeast or other synthetic method. Preferably the ?-tocopherol comprises at least 10% w/w of the composition.

Abstract: An IBTL system having a low GHG footprint for converting biomass to liquid fuels in which a biomass feed is converted to liquids by direct liquefaction and the liquids are upgraded to produce premium fuels. Biomass residues from the direct liquefaction, and optionally additional biomass is pyrolyzed using microwave pyrolysis to produce structured biochar, hydrogen for the liquefaction and upgrading, and CO2 for conversion to algae, including blue green algae (cyanobacteria) in a photobioreactor (PBR). Produced algae and diazotrophic microorganisms are used to produce a biofertilizer that also contains structured biochar. The structured biochar acts as a nucleation agent for the algae in the PBR, as a absorption agent to absorb inorganics from the biomass feed to direct liquefaction or from the liquids produced thereby, and as a water retention agent in the biofertilizer.